ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neulasta (Pegfilgrastim) and Biosimilar Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-25R14574
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Neulasta Pegfilgrastim and Biosimilar Market Research Report 2023
BUY CHAPTERS

Global Neulasta (Pegfilgrastim) and Biosimilar Market Research Report 2025

Code: QYRE-Auto-25R14574
Report
May 2025
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Viatris
Coherus
Amneal Pharmaceutical
Amgen Inc
Fresenius Kabi
Novartis
Pfizer Inc

Neulasta (Pegfilgrastim) and Biosimilar Market Size

The global market for Neulasta (Pegfilgrastim) and Biosimilar was valued at US$ 2737 million in the year 2024 and is projected to reach a revised size of US$ 4228 million by 2031, growing at a CAGR of 6.5% during the forecast period.

Neulasta (Pegfilgrastim) and Biosimilar Market

Neulasta (Pegfilgrastim) and Biosimilar Market

Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
North American market for Neulasta (Pegfilgrastim) and Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neulasta (Pegfilgrastim) and Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Neulasta (Pegfilgrastim) and Biosimilar include Amgen, Viatris, Coherus, Novartis, Pfizer, Amneal Pharmaceutical, Fresenius Kabi, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Neulasta (Pegfilgrastim) and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neulasta (Pegfilgrastim) and Biosimilar.
The Neulasta (Pegfilgrastim) and Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neulasta (Pegfilgrastim) and Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neulasta (Pegfilgrastim) and Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Neulasta (Pegfilgrastim) and Biosimilar Market Report

Report Metric Details
Report Name Neulasta (Pegfilgrastim) and Biosimilar Market
Accounted market size in year US$ 2737 million
Forecasted market size in 2031 US$ 4228 million
CAGR 6.5%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Brand
  • Biosimilar
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Amgen, Viatris, Coherus, Novartis, Pfizer, Amneal Pharmaceutical, Fresenius Kabi
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Neulasta (Pegfilgrastim) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Neulasta (Pegfilgrastim) and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Neulasta (Pegfilgrastim) and Biosimilar Market growing?

Ans: The Neulasta (Pegfilgrastim) and Biosimilar Market witnessing a CAGR of 6.5% during the forecast period 2025-2031.

What is the Neulasta (Pegfilgrastim) and Biosimilar Market size in 2031?

Ans: The Neulasta (Pegfilgrastim) and Biosimilar Market size in 2031 will be US$ 4228 million.

Who are the main players in the Neulasta (Pegfilgrastim) and Biosimilar Market report?

Ans: The main players in the Neulasta (Pegfilgrastim) and Biosimilar Market are Amgen, Viatris, Coherus, Novartis, Pfizer, Amneal Pharmaceutical, Fresenius Kabi

What are the Application segmentation covered in the Neulasta (Pegfilgrastim) and Biosimilar Market report?

Ans: The Applications covered in the Neulasta (Pegfilgrastim) and Biosimilar Market report are Hospital, Pharmacy, Other

What are the Type segmentation covered in the Neulasta (Pegfilgrastim) and Biosimilar Market report?

Ans: The Types covered in the Neulasta (Pegfilgrastim) and Biosimilar Market report are Brand, Biosimilar

Recommended Reports

Biosimilars & Generics

Cell & Gene Therapy

Neutropenia & Immunology

1 Neulasta (Pegfilgrastim) and Biosimilar Market Overview
1.1 Product Definition
1.2 Neulasta (Pegfilgrastim) and Biosimilar by Type
1.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Type (2024 VS 2031)
1.2.2 Brand
1.2.3 Biosimilar
1.3 Neulasta (Pegfilgrastim) and Biosimilar by Application
1.3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Estimates and Forecasts
1.4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue 2020-2031
1.4.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales 2020-2031
1.4.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Neulasta (Pegfilgrastim) and Biosimilar Market Competition by Manufacturers
2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Manufacturers (2020-2025)
2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Neulasta (Pegfilgrastim) and Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Product Type & Application
2.7 Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Date of Enter into This Industry
2.8 Global Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Situation and Trends
2.8.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Neulasta (Pegfilgrastim) and Biosimilar Players Market Share by Revenue
2.8.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Scenario by Region
3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2020-2031
3.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2020-2025
3.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2026-2031
3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2020-2031
3.3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2020-2025
3.3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2026-2031
3.4 North America Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.4.1 North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2031)
3.4.3 North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.5.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2031)
3.5.3 Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Region
3.6.1 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2020-2031)
3.6.3 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.7.1 Latin America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2031)
3.7.3 Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country
3.8.1 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2031)
3.8.3 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2020-2031)
4.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2020-2025)
4.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2026-2031)
4.1.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2020-2031)
4.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2020-2031)
4.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2020-2025)
4.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2026-2031)
4.2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2020-2031)
4.3 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Type (2020-2031)
5 Segment by Application
5.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2020-2031)
5.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2020-2025)
5.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2026-2031)
5.1.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2020-2031)
5.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2020-2031)
5.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2020-2025)
5.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2026-2031)
5.2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2020-2031)
5.3 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Viatris
6.2.1 Viatris Company Information
6.2.2 Viatris Description and Business Overview
6.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.2.5 Viatris Recent Developments/Updates
6.3 Coherus
6.3.1 Coherus Company Information
6.3.2 Coherus Description and Business Overview
6.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.3.5 Coherus Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Amneal Pharmaceutical
6.6.1 Amneal Pharmaceutical Company Information
6.6.2 Amneal Pharmaceutical Description and Business Overview
6.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.6.5 Amneal Pharmaceutical Recent Developments/Updates
6.7 Fresenius Kabi
6.7.1 Fresenius Kabi Company Information
6.7.2 Fresenius Kabi Description and Business Overview
6.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio
6.7.5 Fresenius Kabi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Chain Analysis
7.2 Neulasta (Pegfilgrastim) and Biosimilar Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neulasta (Pegfilgrastim) and Biosimilar Production Mode & Process Analysis
7.4 Neulasta (Pegfilgrastim) and Biosimilar Sales and Marketing
7.4.1 Neulasta (Pegfilgrastim) and Biosimilar Sales Channels
7.4.2 Neulasta (Pegfilgrastim) and Biosimilar Distributors
7.5 Neulasta (Pegfilgrastim) and Biosimilar Customer Analysis
8 Neulasta (Pegfilgrastim) and Biosimilar Market Dynamics
8.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Trends
8.2 Neulasta (Pegfilgrastim) and Biosimilar Market Drivers
8.3 Neulasta (Pegfilgrastim) and Biosimilar Market Challenges
8.4 Neulasta (Pegfilgrastim) and Biosimilar Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Viatris
Coherus
Amneal Pharmaceutical
Amgen Inc
Fresenius Kabi
Novartis
Pfizer Inc
List of Tables
 Table 1. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Neulasta (Pegfilgrastim) and Biosimilar Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Neulasta (Pegfilgrastim) and Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Product Type & Application
 Table 12. Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Neulasta (Pegfilgrastim) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neulasta (Pegfilgrastim) and Biosimilar as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2020-2025) & (K Units)
 Table 18. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2020-2025)
 Table 19. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2026-2031) & (K Units)
 Table 20. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2026-2031)
 Table 21. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2020-2025)
 Table 23. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2026-2031)
 Table 25. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 27. North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 28. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Type (2020-2025)
 Table 51. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Type (2026-2031)
 Table 52. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2020-2025)
 Table 53. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2026-2031)
 Table 54. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2020-2025)
 Table 57. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2026-2031)
 Table 58. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Application (2020-2025)
 Table 61. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Application (2026-2031)
 Table 62. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2020-2025)
 Table 63. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2026-2031)
 Table 64. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2020-2025)
 Table 67. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2026-2031)
 Table 68. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Application (2026-2031)
 Table 70. Amgen Company Information
 Table 71. Amgen Description and Business Overview
 Table 72. Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product
 Table 74. Amgen Recent Developments/Updates
 Table 75. Viatris Company Information
 Table 76. Viatris Description and Business Overview
 Table 77. Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product
 Table 79. Viatris Recent Developments/Updates
 Table 80. Coherus Company Information
 Table 81. Coherus Description and Business Overview
 Table 82. Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product
 Table 84. Coherus Recent Developments/Updates
 Table 85. Novartis Company Information
 Table 86. Novartis Description and Business Overview
 Table 87. Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product
 Table 89. Novartis Recent Developments/Updates
 Table 90. Pfizer Company Information
 Table 91. Pfizer Description and Business Overview
 Table 92. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product
 Table 94. Pfizer Recent Developments/Updates
 Table 95. Amneal Pharmaceutical Company Information
 Table 96. Amneal Pharmaceutical Description and Business Overview
 Table 97. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product
 Table 99. Amneal Pharmaceutical Recent Developments/Updates
 Table 100. Fresenius Kabi Company Information
 Table 101. Fresenius Kabi Description and Business Overview
 Table 102. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product
 Table 104. Fresenius Kabi Recent Developments/Updates
 Table 105. Key Raw Materials Lists
 Table 106. Raw Materials Key Suppliers Lists
 Table 107. Neulasta (Pegfilgrastim) and Biosimilar Distributors List
 Table 108. Neulasta (Pegfilgrastim) and Biosimilar Customers List
 Table 109. Neulasta (Pegfilgrastim) and Biosimilar Market Trends
 Table 110. Neulasta (Pegfilgrastim) and Biosimilar Market Drivers
 Table 111. Neulasta (Pegfilgrastim) and Biosimilar Market Challenges
 Table 112. Neulasta (Pegfilgrastim) and Biosimilar Market Restraints
 Table 113. Research Programs/Design for This Report
 Table 114. Key Data Information from Secondary Sources
 Table 115. Key Data Information from Primary Sources
 Table 116. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Neulasta (Pegfilgrastim) and Biosimilar
 Figure 2. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Type: 2024 & 2031
 Figure 4. Brand Product Picture
 Figure 5. Biosimilar Product Picture
 Figure 6. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application: 2024 & 2031
 Figure 8. Hospital
 Figure 9. Pharmacy
 Figure 10. Other
 Figure 11. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (2020-2031) & (K Units)
 Figure 14. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price (US$/Unit) & (2020-2031)
 Figure 15. Neulasta (Pegfilgrastim) and Biosimilar Report Years Considered
 Figure 16. Neulasta (Pegfilgrastim) and Biosimilar Sales Share by Manufacturers in 2024
 Figure 17. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Neulasta (Pegfilgrastim) and Biosimilar Players: Market Share by Revenue in Neulasta (Pegfilgrastim) and Biosimilar in 2024
 Figure 19. Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 22. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 23. United States Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 26. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2020-2031)
 Figure 34. China Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 42. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 43. Mexico Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Brazil Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Argentina Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2020-2031)
 Figure 47. Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2020-2031)
 Figure 48. Turkey Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Saudi Arabia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. UAE Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Global Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2020-2031)
 Figure 52. Global Revenue Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2020-2031)
 Figure 53. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Type (2020-2031)
 Figure 54. Global Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Application (2020-2031)
 Figure 55. Global Revenue Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Application (2020-2031)
 Figure 56. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Application (2020-2031)
 Figure 57. Neulasta (Pegfilgrastim) and Biosimilar Value Chain
 Figure 58. Channels of Distribution (Direct Vs Distribution)
 Figure 59. Bottom-up and Top-down Approaches for This Report
 Figure 60. Data Triangulation
 Figure 61. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Pegfilgrastim Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Pegfilgrastim Market Insights Forecast to 2030
Global Filgrastim Market Insights Forecast to 2030
Global Human Granulocyte Colony Stimulating Factor for Injection Market Research Report 2024
Global Recombinant Human Granulocyte Colony Stimulating Market Insights Forecast to 2030
Granulocyte Colony Stimulating Factor G CSF Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Human GM CSF for Injection Market Research Report 2024
Global Filgrastim Injection Market Research Report 2024
Global PEGylated Granulocyte Colony Stimulating Factor Market Research Report 2024
Global Granulocyte Colony stimulating Factor G CSF ELISA Kit Market Research Report 2024
Global Chemotherapy Induced Neutropenia CIN Drug Market Research Report 2025
Global Biosimilars and Innovative Biological Drugs Market Research Report 2024
Recombinant Non Glycosylated Proteins Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Migalasta Reagent Market Research Report 2024
Biosimilars Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Biosimilar Insulin Lispro Market
Global Generic vs Innovator Drugs Market Research Report 2024
Global Granulocyte Macrophage Colony Stimulating Factor GM CSF ELISA Kit Market Research Report 2024
Romiplostim Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Oncology Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions